Entrada reports ELEVATE-45-201 Cohort 1 data showing ENTR-601-45 meets safety, tolerability goals
TRDA•Entrada Therapeutics said the first-dose cohort of its Phase 1/2 Duchenne muscular dystrophy trial met its safety and tolerability goals, with early biological activity observed. Enrollment in the higher-dose Cohort 2 is complete, and data are scheduled for the first half of 2027.
1. Cohort 1 results
Entrada Therapeutics reported positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in Duchenne muscular dystrophy. The initial-dose cohort met the study’s main safety and tolerability goal, supporting continued dose escalation; early biological activity was observed, but no functional improvement was expected or seen at this stage.
2. Next trial steps
Enrollment is complete for Cohort 2, which is testing a higher dose, with data scheduled for the first half of 2027. The program targets dosing once every six weeks as a lower-frequency alternative to current weekly regimens.
